Choice of prosthetic heart valve for adult patients

Journal of the American College of Cardiology

Volumn 41, Issue 6, 2003, Pages 893-904

  Rahimtoola, Shahbudin H ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ALLOGRAFT; AORTA VALVE PROSTHESIS; AORTA VALVE REPLACEMENT; ARTICLE; AUTOGRAFT; BIOCOMPATIBILITY; BIOPROSTHESIS; BLEEDING; CLINICAL TRIAL; COMORBIDITY; ENDOCARDITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; MITRAL VALVE PROSTHESIS; MITRAL VALVE REPLACEMENT; MORTALITY; PATIENT ATTITUDE; PRIORITY JOURNAL; SURVIVAL; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0037454165     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02965-0     Document Type: Article

References (69)

1. Treasury of Familiar Quotations. Avenal Books, p. 29.
2. Treasury of Familiar Quotations. Avenal Books, p. 221.
3. Rahimtoola SH. Lessons learned about the determinants of the results of valve surgery. Circulation 1988;78:1503-7.
4. McGoon D. On evaluating valves (editorial). Mayo Clinic Proc 1974;49:233.
5. Rahimtoola SH. Valve replacement - a perspective. Am J Cardiol 1975;35:711-5.
6. Hammermeister KE, Sethi GK, Henderson WC, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000;36:1152-8.
7. Carpentier A, Dubost C. From xenograft to bioprosthesis. In: Inoescu MI, Ross DN, Wooler GH, editors. Biological Tissue in Heart Valve Replacement. London: Butterworth, 1971:515-41.
8. Bloomfield P, Wheatley DJ, Prescott RJ, Miller HC. Twelve-year comparison of a Bjork-Shiley mechanical heart-valve with porcine bioprosthesis. N Engl J Med 1991;324:573-9.
9. Orszulak TA, Schaff HV, Puga FJ, et al. Event status of the Start-Edwards aortic valve to 20 years: a benchmark for comparison. Ann Thorac Surg 1997;63:620-6.
10. Lindblom D. Long-term clinical results after aortic valve replacement with the Bjork-Shiley prosthesis. J Thorac Cardiovasc Surg 1988;95:658-67.
11. Lund O, Nielson SL, Arildsen H, Ilkjaer LB, Pilegard HK. Standard aortic St. Jude valve at 18 years: performance profile and determinants of outcome. Ann Thorac Surg 2000;69:1459-65.
12. Butchart EG, Li HH, Payne N, Buchan K, Grunkemeier GL. Twenty years experience with the Medtronic hall valve. J Thorac Cardiovasc Surg 2001;121:1090-100.
13. Peterseim DS, Chen Y-Y, Cheruvu S, et al. Long-term outcome after biological versus mechanical aortic valve replacement in 841 patients. J Thorac Cardiovasc Surg 1999;117:890-7.
14. Yun KL, Miller DC, Moore KA, et al. Durability of the Hancock MO bioprosthesis compared with the standard aortic valve bioprosthesis. Ann Thorac Surg 1995;60:S221-228.
15. Jamieson WRE, Burr LH, Munro AI, Tyers FO, Miyagishima RT. Carpentier-Edwards supra-annular porcine bioprosthesis: clinical performance to twelve years. Ann Thorac Surg 1995;60:S235-240.
16. Cohn LH, Collins JJ, Jr., Rizzo RJ, Adams DH, Cooper GS, Avanki SF. Twenty-year follow-up of the Hancock modified orifice porcine aortic valve. Ann Thorac Surg 1998;66:S30-34.
17. Khan SS, Chaux A, Blanche C, et al. A 20-year experience with the Hancock porcine xenograft in the elderly. Ann Thorac Surg 1998;66:S35-39.
18. Frater RWM, Furlong P, Cosgrove DM, et al. Long-term durability and patient functional status of the Carpentier-Edwards Perimount pericardial bioprosthesis in the aortic position. J Heart Valve Dis 1998;7:48-53.
19. David TE, Ivanor J, Armstrong S, Feindel CM, Cohen G. Late results of heart valve replacement with the Hancock II bioprosthesis. J Thorac Cardiovasc Surg 2001;121:268-78.
20. Lindblom D. Long-term clinical results after mitral valve replacement with Bjork-Shiley prosthesis. J Thorac Cardiovasc Surg 1988;95:321-33.
21. Remadi JP, Baron O, Roussel C, et al. Isolated mitral valve replacement with St. Jude medical prosthesis: long-term results: a follow-up of 19 years. Circulation 2001;103:1542-5.
22. Grunkemeier GL, Li H-H, Starr A. Heart valve replacement: a statistical review of 35 years results. J Heart Valve Dis 1999;8:466-71.
23. Smith N, McAnulty JH, Rahimtoola SH. Severe aortic stenosis with impaired left ventricular function and clinical heart failure: results of valve replacement. Circulation 1978;58:255-64.
24. Rahimtoola SH. Perspective on valvular heart disease: an update. J Am Coll Cardiol 1989;14:1-23.
25. Rahimtoola SH, Frye RL. Valvular heart disease. Circulation 2000;102:IV24-33.
26. Murday A, Miles J, Treasure T, Whitley E. A Prospective Randomized Trial of St. Jude Versus Starr-Edwards Aortic and Mitral Valve Prosthesis. 1998 ECATS Meeting Minutes 1998:80.
27. Johnson DM, Sapirstein W. FDA's requirements for in-vivo performance data for prosthetic heart valves. J Heart Valve Dis 1994;3:350-5.
28. Grunkemeier GL, Anderson WN, Jr. Clinical evaluation and analysis of heart valve substitute. J Heart Valve Dis 1998;7:163-9.
29. Grunkemeier GL, Li H-H, Naftel DC, Starr A, Rahimtoola SH. Long-term performance of heart valve prosthesis. Curr Probl Cardiol 2000;25:73-156.
30. Bonow RO, Carabello B, deLeon AC Jr., et al. ACC/AHA guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 1998;32:1486-588.
31. Butchart EG, Lewis PA, Bethel JA, Brekenridge IM. Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors: recommendations for the medtronic hall valve. Circulation 1991;84 Suppl III:61-9.
32. Butchart EG, Ionescu A, Payne N, Westmoreland D, Fraser A, Grunkemeier G. Serological evidence of previous infection with Clamydia pneumoniae is the strongest predictor of thromboembolism after valve replacement (abstr). Circulation 2001;104:II762.
33. Peterson P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thrombo-embolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-9.
34. BAATAF Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
35. SPAF Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation 1991;84:527-39.
36. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation (CAFA) study. J Am Coll Cardiol 1991;18:349-55.
37. Ezekowitz MD, Bridgers SL, Jame KE, et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
38. EAFT Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;342:1255-62.
39. Aupart M, Diemont F, Babuty D, Fauchier L, Sivinelli A, Marchand M. Resultats intermediares avec la prosthese valvulaire a ailettes carbo medics. Arch Mal Couer Vaiss 1997;90:457-62.
40. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633-8.
41. Marquez S, Hon RT, Yogonathan AP. Comparative hydrodynamic evaluation of bioprosthetic heart valves (abstr). J Heart Valve Dis 2001.
42. Rao V, Jamieson WRE, Ivanor J, Armstrong S, David T. Prosthesis-patient mismatch affects survival after aortic valve replacement. Circulation 2000;102 Suppl III:III5-9.
43. Grunkemeier GL, Bodnar E. Comparative assessment of bioprosthesis durability in the aortic position. J Heart Valve Dis 1995;4:49-55.
44. David TE, Feindel CM, Scully HE, Bos J, Rakowski H. Aortic valve replacement with stentless porcine aortic valves: a ten-year experience. J Heart Valve Dis 1998;7:250-4.
45. Rahimtoola SH. The problem of valve prosthesis-patient mismatch. Circulation 1978;58:20-4.
46. Rahimtoola SH, Murphy E. Valve prosthesis-patient mismatch: long-term sequels. Br Heart J 1981;45:331-5.
47. Rahimtoola SH. Valve prosthesis-patient mismatch: an update. J Heart Valve Dis 1998;7:207-10.
48. Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prostheses-patient mismatch in the aortic valve position and its prevention. J Am Coll Cardiol 2000;36:1131-41.
49. Connolly HM, Oh JK, Schaff HV, et al. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction: result of aortic valve replacement in 52 patients. Circulation 2000;101:1940-6.
50. Medalion B, Blackstone EH, Lytle BW, White J, Arnold JH, Cosgrove DM. Aortic valve replacement: is valve size important? J Thorac Cardiovasc Surg 2000;119:963-74.
51. Hé GW, Grunkemeier GL, Gately HL, Furnary AP, Starr A. Up to thirty-year survival after aortic valve replacement in the small aortic root. Ann Thorac Surg 1995;59:1056-62.
52. Natsuaki M, Itoh T, Tomita S, Naitoh K. Hemodynamics after aortic valve replacement by St. Jude medical valve for patients with small aortic annulus and severe left ventricular hypertrophy. J Heart Valve Dis 1998;7:86-93.
53. Hachida M, Koyangi H, Nonoyama M, Bonkohara Y, Saitu S, Nakamura K. Serial hemodynamic study of aortic valve replacement in patients with narrow aortic roots. J Heart Valve Dis 1998;7:81-5.
54. Pibarot P, Dumesnil JG, Lemieux M, Cartier P, Metras J, Durand L-G. Impact of prosthesis-patient mismatch on hemodynamic and symptomatic status, morbidity and mortality after aortic valve replacement with bioprosthetic heart valve. J Heart Valve Dis 1998;7:211-8.
55. Milano AD, DeCarlo M, Mecozzi G, et al. Clinical outcome in patients with 19mm and 21mm St. Jude aortic prostheses: comparison at long term follow-up. Ann Thorac Surg 2002;73:37-43.
56. Khuri SF, Foiland ED, Sethi GK, et al. Six month post-operative hemodynamics of the Hancock heterograft and the Bjork-Shiley prosthesis: results of the Veterans Administration Cooperative Prospective Randomized trial. J Am Coll Cardiol 1988;12:8-18.
57. O'Brien MF, McGiffin DC, Stafford EG, Gardner MAH, Pohlner PF, McGiffin DC. A comparison of aortic valve replacement with viable cryopreserved and fresh allograft valves, with a note on chromosomal studies. J Thorac Cardiovasc Surg 1987;94:812-23.
58. O'Brien MF, McGriffin DC, Stafford EG, et al. Allograft aortic valve replacement: long-term comparative clinical analysis of the viable cryopreserved and antibiotic 4°C stored valves. J Cardiac Surg 1991;6 Suppl 4:534-43.
59. O'Brien MF, Hancock S, Stafford EG, et al. The homograft aortic valve: a 29-year, 99.3% follow-up of 1,022 valve replacements. J Heart Valve Dis 2001;10:334-44.
60. Palka P, Havrocks S, Lange A, Burstow D, O'Brien MF. Primary aortic valve replacement with cryopreserved aortic allograft: an echographic follow-up study of 570 patients. Circulation 2002;105:61-6.
61. Ross DN. The pulmonary autograft: the Ross principle (or Ross procedural confusion). J Heart Valve Dis 2000;9:174-5.
62. Dore A, Somverville J. Pregnancy in patients with pulmonary autograft valve replacement. Eur Heart J 1997;18:1659-62.
63. Choudhary SK, Mather A, Chandler H, et al. Aortic valve replacement with biological substitute. J Cardiac Surg 1998;13:1-8.
64. Pieters FA, Al-Halees Z, Hatle L, Shahid MS, Al-Amri M. Results of the Ross operation in rheumatic versus non-rheumatic aortic valve disease. J Heart Valve Dis 2000;9:38-44.
65. Matsuki O, Okita Y, Almeida RS, et al. Two decades experience with aortic valve replacement with pulmonary autograft. J Thoracic Cardiovasc Surg 1988;95:705-11.
66. Ross D, Jackson M, Davies J. Pulmonary autograft aortic valve replacement: long-term results. J Cardiac Surg 1991;6 Suppl:529-33.
67. Ross D, Jackson M, Davies J. The pulmonary autograft - a permanent aortic valve. Eur J Cardiothorac Surg 1992;6:113-7.
68. Chambers JC, Somerville J, Stone S, Ross DN. Pulmonary autograft procedure for aortic valve disease: long-term results of the Pioneer series. Circulation 1997;96:2206-14.
69. Oury JH, Hiro SP, Maxwell JM, Lamberto JJ, Duran CMG. The Ross procedure: current registry results. Ann Thorac Surg 1998;66:S162-165.